Latest Articles

Publication Date
All News Scientific
Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan - The Manila Times

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan The Manila Times

Published: Jan. 29, 2026, 1:43 p.m.
Read Full Article
Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction - Quiver Quantitative

Aprea Therapeutics Reports Early Clinical Activity of APR-1051 in Advanced Endometrial Cancer with Significant Tumor Reduction Quiver Quantitative

Published: Jan. 29, 2026, 1:31 p.m.
Read Full Article
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - The Manila Times

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress The Manila Times

Published: Jan. 23, 2026, 1:20 p.m.
Read Full Article
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress - manilatimes.net

Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress manilatimes.net

Published: Jan. 23, 2026, 1:20 p.m.
Read Full Article
Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com - Investing.com Nigeria

Acrivon Therapeutics COO Devroe buys $17k in shares By Investing.com Investing.com Nigeria

Published: Jan. 16, 2026, 3:14 a.m.
Read Full Article
Acrivon Therapeutics COO Devroe buys $17k in shares - Investing.com

Acrivon Therapeutics COO Devroe buys $17k in shares Investing.com

Published: Jan. 15, 2026, 11:55 p.m.
Read Full Article
Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan - Defense World

Acrivon Therapeutics Spotlights ACR368 Endometrial Cancer Data, Adds Serous Arm 3 and FDA Phase 3 Plan Defense World

Published: Jan. 10, 2026, 6:12 a.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com UK

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com UK

Published: Jan. 9, 2026, 2:25 p.m.
Read Full Article
Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data - Investing.com

Piper Sandler raises Acrivon Therapeutics stock price target to $8 on positive cancer data Investing.com

Published: Jan. 9, 2026, 1:59 p.m.
Read Full Article
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 - Sahm

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 …

Published: Jan. 9, 2026, 6:18 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!